FIA
SAGE

FNY Investment Advisers’s Sage Therapeutics SAGE Stock Holding History

FNY Investment Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-129
Closed -$9K – 771
2019
Q4 		$9K Buy
+129
New +$15.9K ﹤0.01% 647

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FNY Investment Advisers's SAGE Position: Q1 2020 in Review

FNY Investment Advisers sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 129 shares — an estimated $9K sold.

FNY Investment Advisers first reported a position in SAGE in Q4 2019 and held it in 1 quarter. The position peaked at $9K in Q4 2019. 229 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • FNY Investment Advisers reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • FNY Investment Advisers sold 129 Sage Therapeutics shares in Q1 2020, an estimated $9K.
  • FNY Investment Advisers first reported a position in Sage Therapeutics in Q4 2019 and held it in 1 quarter.
  • FNY Investment Advisers's Sage Therapeutics position peaked at $9K in Q4 2019.
  • 229 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on FNY Investment Advisers's 13F filing for Q1 2020, filed 9 Apr 2020.